Trial Profile
A Randomized, Double-masked, Placebo- and Active- Controlled, Parallel-group, Multi-center, Dose-response Trial of DE-104 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 May 2014
Price :
$35
*
At a glance
- Drugs DE 104 (Primary) ; Latanoprost
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Santen Pharmaceutical
- 16 May 2014 New trial record